10-Q: Niagen Bioscience Reports Strong Q1 2025 Results, Driven by Consumer and Ingredient Sales Growth

Niagen Bioscience announces a profitable first quarter in 2025, driven by significant growth in both consumer product and ingredient sales.

Summary

• Niagen Bioscience, formerly ChromaDex Corporation, reported its Q1 2025 financial results.
• Net sales increased by 38% to $30.481 million, compared to $22.153 million in Q1 2024.
• The company achieved net income of $5.063 million, a significant turnaround from a net loss of $0.492 million in the same period last year.
• Basic income per share was $0.07, while diluted income per share was $0.06.
• The increase in net sales was primarily driven by a $4.2 million increase in Tru Niagen sales and a $4.1 million increase in ingredient sales.
• The company's operating activities provided cash of $7.9 million.
• As of March 31, 2025, the company had unrestricted cash and cash equivalents of $55.5 million.
• The company has three reportable segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services.

Sentiment

Score: 8

Explanation: The document presents a positive financial outlook with strong growth in sales and a return to profitability. However, ongoing litigation and reliance on a single supplier introduce some risk.

Positives

• The company achieved net income of $5.1 million in Q1 2025, a significant improvement from the $0.5 million loss in Q1 2024.
• Total net sales increased by 38% year-over-year, reaching $30.5 million.
• Consumer Products segment sales increased by 24% to $21.5 million, driven by e-commerce growth.
• Ingredients segment sales doubled, reaching $8.2 million, boosted by food-grade and pharmaceutical-grade Niagen sales.
• The company's operating activities generated $7.9 million in cash.
• The company has $55.5 million in unrestricted cash and cash equivalents as of March 31, 2025.
• Cost of sales, as a percentage of net sales, improved by 270 basis points reflecting enhanced operational efficiency and favorable product mix shifts across segments.

Negatives

• The company is still involved in ongoing litigation with Elysium Health, with potential liability of approximately $10.4 million if the company is not successful in its appeal.
• The company relies on a single supplier, W.R. Grace, for NRC, which poses a risk to the supply chain.
• The company has purchase obligations of $16.4 million related to inventory purchase commitments to be paid during the six-month period from April 1, 2025 to September 30, 2025.

Risks

• The company's future capital requirements will be influenced by several factors, including cash flows from operations, sales growth, optimized gross profit margins, reduced selling and marketing expense as a percentage of net sales, continued customer relationship development, and the ability to successfully market new and existing products.
• The company may need additional financing to implement its long-term business plan.
• There can be no assurance that any such financing will be available on terms favorable to the company or at all.
• The company is involved in ongoing litigation with Elysium Health, with potential liability of approximately $10.4 million if the company is not successful in its appeal.
• The company relies on a single supplier, W.R. Grace, for NRC, which poses a risk to the supply chain.
• The company has purchase obligations of $16.4 million related to inventory purchase commitments to be paid during the six-month period from April 1, 2025 to September 30, 2025.
• The company is subject to global events beyond its control, including war, public health crises, trade disputes, economic sanctions, trade wars and their collateral impacts and other international events.

Future Outlook

Management anticipates that its current unrestricted cash and cash equivalents and cash to be generated from net sales will be sufficient to meet its financial obligations as they become due over at least the next twelve months. The Company may, however, seek additional capital within the next twelve months, both to fund its projected operating plans after the next twelve months and/or to fund the Company's longer-term strategic objectives.

Industry Context

The company operates in the growing wellness and dietary supplement market, with a focus on NAD+ precursors and healthy aging. The results reflect increasing consumer interest in these products.

Comparison to Industry Standards

• It's difficult to provide a precise comparison without knowing the specific growth rates of Niagen Bioscience's direct competitors in the NAD+ precursor market.
• However, the 38% revenue growth significantly outpaces the average growth rate of the broader dietary supplement industry, which typically sees single-digit percentage growth annually.
• Comparable companies in the broader nutraceutical space include Herbalife Nutrition, Nu Skin Enterprises, and USANA Health Sciences.
• These companies often serve as benchmarks for revenue growth, profitability, and market capitalization.
• Niagen Bioscience's focus on scientific validation and research partnerships differentiates it from some competitors in the dietary supplement market.

Legal Proceedings

• The company is involved in ongoing litigation with Elysium Health, LLC regarding patent infringement and breach of contract claims.
• The court granted Elysium's motion for attorneys fees and costs, awarding $9.2 million, plus judgment interest.
• Niagen Bioscience has appealed the final judgment to the U.S. Court of Appeals for the Federal Circuit.
• The company believes the Court abused its discretion in granting the award.
• The company received warning letters from the United States FDA and Federal Trade Commission (FTC) regarding statements relating to preclinical and clinical research results involving nicotinamide riboside and COVID-19.

Related Party Transactions

• Prior to August 20, 2024, A.S. Watson Group was considered a related party through common ownership.
• On August 20, 2024, this entity sold its ownership in the Company, and A.S. Watson Group ceased to be a related party as of that date.
• The company had no trade receivables connected to related parties as of March 31, 2025 or December 31, 2024.
• The sale of consumer products to related parties during the periods indicated are as follows: A.S. Watson Group Former Related Party $3.0 million.

Stakeholder Impact

• Shareholders: Positive results may lead to increased stock value.
• Employees: Improved financial performance could lead to increased job security and potential bonuses.
• Customers: Continued product availability and potential for new product development.
• Suppliers: Increased sales could lead to increased orders and stronger relationships.
• Creditors: Improved financial health reduces risk of default.

Next Steps

• The company expects to continue to negotiate a potential longer-term supply agreement with W.R. Grace.
• The company will continue to pursue its appeal in the Elysium Health litigation.
• The company may seek additional funds to support both its short-term and long-term operating objectives.

Key Dates

Keywords

Niagen, Bioscience, ChromaDex, NAD+, nicotinamide riboside, Tru Niagen, financial results, Q1 2025, sales growth, ingredients, consumer products, litigation, W.R. Grace, supply chain